INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 1.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $979,342 | +141.8% | 52,824 | +44.3% | 0.00% | – |
| Q2 2023 | $405,006 | +88136.6% | 36,619 | +7.1% | 0.00% | -100.0% |
| Q1 2023 | $459 | +12.2% | 34,183 | +3.3% | 0.00% | 0.0% |
| Q4 2022 | $409 | -99.9% | 33,094 | +5.1% | 0.00% | 0.0% |
| Q3 2022 | $439,000 | +8.1% | 31,496 | +7.1% | 0.00% | 0.0% |
| Q2 2022 | $406,000 | -11.5% | 29,409 | +4.3% | 0.00% | 0.0% |
| Q1 2022 | $459,000 | -12.1% | 28,199 | -12.0% | 0.00% | 0.0% |
| Q4 2021 | $522,000 | +8.8% | 32,031 | -1.0% | 0.00% | 0.0% |
| Q3 2021 | $480,000 | -23.3% | 32,354 | +3.2% | 0.00% | 0.0% |
| Q2 2021 | $626,000 | -12.1% | 31,353 | +1.6% | 0.00% | 0.0% |
| Q1 2021 | $712,000 | -10.2% | 30,853 | -3.9% | 0.00% | 0.0% |
| Q4 2020 | $793,000 | -39.0% | 32,109 | +2.4% | 0.00% | -50.0% |
| Q3 2020 | $1,300,000 | -33.9% | 31,360 | -23.6% | 0.00% | -33.3% |
| Q2 2020 | $1,966,000 | -14.3% | 41,045 | +12.6% | 0.00% | -40.0% |
| Q1 2020 | $2,294,000 | -48.4% | 36,442 | +1.7% | 0.01% | -28.6% |
| Q4 2019 | $4,442,000 | +104.6% | 35,848 | +9.6% | 0.01% | +75.0% |
| Q3 2019 | $2,171,000 | -16.7% | 32,709 | -0.2% | 0.00% | -20.0% |
| Q2 2019 | $2,607,000 | -19.4% | 32,764 | +13.3% | 0.01% | -16.7% |
| Q1 2019 | $3,234,000 | +10.1% | 28,914 | -0.8% | 0.01% | 0.0% |
| Q4 2018 | $2,937,000 | +18.2% | 29,139 | +48.1% | 0.01% | +20.0% |
| Q3 2018 | $2,485,000 | +40.0% | 19,669 | -7.0% | 0.01% | +25.0% |
| Q2 2018 | $1,775,000 | +52.1% | 21,153 | +11.5% | 0.00% | +100.0% |
| Q1 2018 | $1,167,000 | +2.6% | 18,972 | -2.5% | 0.00% | 0.0% |
| Q4 2017 | $1,137,000 | -1.7% | 19,464 | -2.4% | 0.00% | -33.3% |
| Q3 2017 | $1,157,000 | -52.8% | 19,939 | -1.5% | 0.00% | -50.0% |
| Q2 2017 | $2,451,000 | +11.0% | 20,244 | +3.7% | 0.01% | +20.0% |
| Q1 2017 | $2,209,000 | +4.0% | 19,531 | -0.1% | 0.01% | 0.0% |
| Q4 2016 | $2,125,000 | -28.4% | 19,556 | +8.5% | 0.01% | -37.5% |
| Q3 2016 | $2,966,000 | +20.2% | 18,020 | +4.2% | 0.01% | +14.3% |
| Q2 2016 | $2,467,000 | +23.0% | 17,293 | +10.7% | 0.01% | +16.7% |
| Q1 2016 | $2,006,000 | -15.3% | 15,618 | -1.5% | 0.01% | -25.0% |
| Q4 2015 | $2,367,000 | -9.3% | 15,849 | +0.7% | 0.01% | -11.1% |
| Q3 2015 | $2,611,000 | -28.6% | 15,740 | +3.8% | 0.01% | -25.0% |
| Q2 2015 | $3,659,000 | +18.9% | 15,160 | +39.0% | 0.01% | +33.3% |
| Q1 2015 | $3,077,000 | +93.6% | 10,910 | +7.1% | 0.01% | +80.0% |
| Q4 2014 | $1,589,000 | -43.2% | 10,185 | -13.8% | 0.01% | -37.5% |
| Q3 2014 | $2,798,000 | +19.7% | 11,820 | +19.7% | 0.01% | +14.3% |
| Q2 2014 | $2,337,000 | +0.1% | 9,878 | +39.5% | 0.01% | 0.0% |
| Q1 2014 | $2,335,000 | +436.8% | 7,079 | +11.0% | 0.01% | +600.0% |
| Q4 2013 | $435,000 | +9.0% | 6,377 | +10.2% | 0.00% | 0.0% |
| Q3 2013 | $399,000 | +56.5% | 5,787 | +1.7% | 0.00% | 0.0% |
| Q2 2013 | $255,000 | – | 5,692 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |